Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016', provides in depth analysis on HIV 1 Integrase (EC 2.7.7.) targeted pipeline therapeutics. The report provides comprehensive information on the HIV 1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for HIV 1 Integrase (EC 2.7.7.) - The report reviews HIV 1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects - The report assesses HIV 1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to HIV 1 Integrase (EC 2.7.7.) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for HIV 1 Integrase (EC 2.7.7.) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding HIV 1 Integrase (EC 2.7.7.) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 HIV 1 Integrase (EC 2.7.7.) Overview 7 Therapeutics Development 8 HIV 1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development 8 HIV 1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area 9 HIV 1 Integrase (EC 2.7.7.) - Products under Development by Indication 10 HIV 1 Integrase (EC 2.7.7.) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 HIV 1 Integrase (EC 2.7.7.) - Products under Development by Companies 13 HIV 1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes 15 HIV 1 Integrase (EC 2.7.7.) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 HIV 1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development 23 Critical Outcome Technologies Inc 23 Gilead Sciences Inc 24 Merck & Co Inc 25 TGV-Laboratories 26 ViiV Healthcare Ltd 27 HIV 1 Integrase (EC 2.7.7.) - Drug Profiles 28 (bictegravir sodium +emtricitabine + tenofovir alafenamide) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 (dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 cabotegravir sodium - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 cabotegravir sodium + rilpivirine hydrochloride - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 elvitegravir - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 M-522 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 M-532 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 MK-2048 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Inhibit HIV-1 Integrase for HIV infection - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule to Inhibit Integrase for HIV - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 T-169 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 HIV 1 Integrase (EC 2.7.7.) - Dormant Projects 46 HIV 1 Integrase (EC 2.7.7.) - Discontinued Products 47 HIV 1 Integrase (EC 2.7.7.) - Featured News & Press Releases 48 Nov 18, 2016: ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen 48 Jul 26, 2016: SMILE Trial Launch - investigating a potentially lower toxicity, simplified treatment regimen for HIV infected children 48 Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir 49 Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment 50 Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy 51 May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy 52 Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment 52 Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys 53 Apr 21, 2014: Gilead Sciences' New Drug Applications for Elvitegravir for HIV Therapy Accepted by U.S. FDA 54 Nov 18, 2013: European Commission Approves Gilead's Vitekta, an Integrase Inhibitor for the Treatment of HIV-1 Infection 54 Sep 19, 2013: Gilead Sciences Receives CHMP Positive Opinion For Vitekta For Treatment Of Human Immunodeficiency Virus-1 Infection In Adults 55 Jul 03, 2013: Monthly Injections With GSK And J&J's Combination Therapy Sustained Drug Levels In Blood To Control HIV, Study Shows 56 Apr 29, 2013: Gilead Sciences Receives Complete Response Letter From FDA For Elvitegravir 56 May 20, 2010: Critical Outcome Technologies Inc. Discovers Novel Scaffolds For Inhibiting HIV Integrase 57 Apr 13, 2010: Critical Outcome Technologies Inc. Provides Update On HIV-1 Integrase Co-Development Program 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Critical Outcome Technologies Inc, H2 2016 23 Pipeline by Gilead Sciences Inc, H2 2016 24 Pipeline by Merck & Co Inc, H2 2016 25 Pipeline by TGV-Laboratories, H2 2016 26 Pipeline by ViiV Healthcare Ltd, H2 2016 27 Dormant Projects, H2 2016 46 Discontinued Products, H2 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
